8-K: Jasper Therapeutics Announces Positive Results from Briquilimab Study in Chronic Inducible Urticaria

Jasper Therapeutics reported that 93% of participants in their SPOTLIGHT study achieved a clinical response to briquilimab for chronic inducible urticaria, with 83% of the 120mg cohort achieving a complete response.

Summary

• Jasper Therapeutics announced positive preliminary data from its SPOTLIGHT Phase 1b/2a study of briquilimab in patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
• The study enrolled 15 participants across two dose cohorts (40mg and 120mg), with 14 of 15 participants (93%) achieving a clinical response within 6 weeks.
• In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response, and 1 participant experienced a partial response.
• Briquilimab was well tolerated, with no serious adverse events or grade 3 or higher adverse events reported.
• The company has obtained regulatory clearance to enroll a 180mg dose cohort in the SPOTLIGHT study.
• Full data from the SPOTLIGHT study is expected in the first half of 2025.
• Initial data from the BEACON study in chronic spontaneous urticaria (CSU) is expected the week of January 6th, 2025, including a 180mg Q8W dose cohort.
• Mean baseline serum tryptase for participants in the 120mg cohort was 7.6 ng/ml, with a 66% reduction observed at 2 weeks following treatment.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a high response rate and good safety profile, indicating a strong potential for the drug. The management comments are also very positive, further boosting the sentiment.

Positives

• The study showed a high rate of clinical response, with 93% of participants responding to treatment.
• A significant portion of patients in the 120mg cohort, 83%, achieved a complete response.
• Briquilimab was well tolerated with no serious adverse events or high-grade adverse events.
• The treatment led to a significant reduction in tryptase levels, indicating a biological effect.
• The company is expanding the study to include a 180mg dose cohort.

Negatives

• The study is still ongoing, and full results are not yet available.
• The results are preliminary and may change as more data is collected.
• The study only included a small number of participants.

Risks

• The study results are preliminary and may not be replicated in larger trials.
• The company is still in the clinical stage and may not receive regulatory approvals.
• There is a risk that the product may not be successfully commercialized.
• The company faces competition from other pharmaceutical companies.
• The company's business could be affected by health epidemics.

Future Outlook

The company expects to present full data from the SPOTLIGHT study in the first half of 2025 and initial data from the BEACON study in the week of January 6th, 2025.

Management Comments

• Ronald Martell, President and CEO, stated that the results demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable clinical benefit along with a potentially differentiated safety profile.
• Martin Metz, M.D., Professor of Dermatology and Allergy, expressed excitement about the initial clinical data and the safety profile observed in the SPOTLIGHT study.

Industry Context

This announcement is significant as it provides positive data for a novel therapy targeting mast cell driven diseases, which are often difficult to treat. The results could position Jasper Therapeutics as a key player in the treatment of chronic urticaria.

Comparison to Industry Standards

• The reported 83% complete response rate in the 120mg cohort of the SPOTLIGHT study is notably high compared to existing treatments for chronic inducible urticaria, which often have lower efficacy rates.
• Many current treatments for urticaria, such as antihistamines, often fail to provide adequate relief for patients, making the high response rate of briquilimab a significant improvement.
• The lack of serious adverse events and high-grade adverse events in the study is also a positive differentiator compared to some other therapies that may have more significant side effects.
• Companies like Novartis and Genentech have treatments for chronic spontaneous urticaria, but the focus on chronic inducible urticaria with briquilimab is a differentiating factor for Jasper Therapeutics.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical results.
• Patients with chronic inducible urticaria may have a new treatment option with potentially high efficacy.
• Employees of Jasper Therapeutics may be motivated by the positive results and the potential for the drug to reach the market.

Next Steps

• Jasper will enroll a 180mg dose cohort in the SPOTLIGHT study.
• The company will present full data from the SPOTLIGHT study in the first half of 2025.
• Jasper will report initial data from the BEACON study in the week of January 6th, 2025.

Key Dates

Keywords

briquilimab, chronic inducible urticaria, cold urticaria, symptomatic dermographism, mast cell, c-Kit, clinical trial, SPOTLIGHT study, BEACON study, biotechnology